The Educational Programmes on this page cover the following items:
Advanced PET Imaging in Prostate Cancer
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer
Adjuvant Therapy in mRCC
This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC
GU CONNECT Update from…
GU CONNECT Update from ESMO 2018
GU CONNECT has summarised the highlights from ESMO 2018 for you.
ASCO GU 2018
Update from San Francisco 2018
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
A CONNECT Update from Madrid
GU CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.
ASCO GU 2017
GU CONNECT update from Orlando
GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you
Your clinical questions answered
Please submit your clinical topic for the next GU CONNECT newsletter here.
An update on the treatment of patients with mCRPC with RA-223 plus AAP
Dr. Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC
Advances in metastatic hormone-sensitive prostate cancer
Associate Professor Alicia Morgans provides her thoughts on the recent advances in metastatic hormone-sensitive prostate cancer
How to use combination, sequential and immuno-oncology therapies in mCRPC?
Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer)
An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients
Dr. Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.
Relevant papers discussed